

1 **Elevated serum creatinine and hyponatraemia as prognostic factors in canine acute pancreatitis**

2 V Marchetti,a* E Gori,a I Lippi,a E Luchetti a,ML Manca b and A Pierini a

3 a Veterinary Teaching Hospital ‘Mario Modenato’, Department of Veterinary Sciences, University of Pisa,

4 Via Livornese Lato monte, San Piero a Grado 56122, Pisa, Italy

5 b Department of Clinical and Experimental Medicine, University of Pisa, Italy

6

7 **ABSTRACT**

8 **Objective** To evaluate prognostic factors for canine acute pancreatitis (AP) based on clinical and laboratory
9 data that can be easily assessed in veterinary practice.

10 **Design** Retrospective study between January 2010 and December 2013.

11 **Methods** The diagnosis of AP was based on clinical signs and an abnormal SNAP® cPL™ test result,
12 concurrently with an ultrasound pattern suggestive of pancreatitis. Dogs were divided into survivors and non-
13 survivors. We evaluated 12 clinical and laboratory parameters: respiratory rate, rectal temperature, white
14 blood cells, haematocrit, total serum proteins, albumin, creatinine, cholesterol, total and ionised calcium,
15 sodium and potassium. Clinical and clinicopathological data were statistically compared between survivors
16 and non-survivors. A value of $P < 0.05$ was considered significant and $P < 0.01$ as highly significant. The
17 odds ratio (OR) was calculated.

18 **Results** The study enrolled 50 client-owned dogs with a diagnosis of AP. Serum creatinine ($P = 0.017$) and
19 sodium ($P = 0.004$) correlated significantly with the outcome. Serum sodium < 139.0 mmol/L (139.0 mEq/L)
20 and serum creatinine > 212 μ mol/L (2.4 mg/dL) were associated significantly with poor prognosis.

21 Azotaemia (OR 12.5; 95% confidence interval (CI) 1.32–118.48) and hyponatraemia (OR 4.9; 95% CI 1.36–
22 17.64) were associated with increased risk of death.

23 **Conclusions** In dogs with AP, hyponatraemia and azotaemia seem to be significantly associated with an
24 increased risk of death.

25

26 **Introduction**

27 in veterinary medicine, acute pancreatitis (AP) is a relatively frequent pathological condition. Although AP is
28 generally regarded as a significant illness in dogs, its actual incidence is unknown. Some dogs have subclinical

29 or mild disease and recover within a few days without specific treatment. However, others show more severe
30 forms, which may result in death if not promptly recognised and treated.^{1,2} An early assessment of disease
31 severity and the identification of risk factors, is thus essential for the appropriate management of AP.²
32 Scoring systems based on the careful monitoring of patients in an intensive care unit are commonly used in
33 human medicine.³⁻⁶ The acute physiology and chronic health evaluation system (APACHE) is considered as
34 the most sensitive model, able to make prognosis within the first 24 h, with an accuracy of 90%. Clinical
35 parameters included in the APACHE classification system are body temperature, mean arterial pressure, heart
36 and respiratory rates, oxygen partial pressure, arterial pH, sodium and potassium ions, serum creatinine,
37 haematocrit (Hct) and white blood cells (WBC).⁷
38 In veterinary medicine, two recent studies evaluated the prognosis and outcome of AP in dogs. Mansfield et
39 al.⁸ developed a clinical severity index to report the outcome in dogs with an ultrasound or histological
40 diagnosis of AP. An elevated clinical severity index score was associated with higher mortality rate.
41 Another study found that hypothermia and metabolic acidosis correlated significantly with poor prognosis.²
42 The aim of the present study was to evaluate the prognostic factors for canine AP based exclusively on clinical
43 and laboratory data that can be easily assessed in veterinary practice.

44

45 **Materials and methods**

46 For the present study, an evaluation of the database of all dogs admitted to the University of Pisa Veterinary
47 Teaching Hospital between January 2010 and December 2013 was performed in order to identify dogs with
48 AP. The diagnosis of AP was based on the following criteria: (1) ≥ 2 of the following clinical signs: abdominal
49 pain, polyuria/polydipsia, diarrhoea, vomiting or anorexia/dysorexia for fewer than 7 days, (2) ultrasound
50 evidence of AP (Xario XG ultrasound unit, Toshiba, Tokyo, Japan) without other identifiable
51 diseases and (3) abnormal SNAP® cPL™ test (Idexx Laboratories, Milan, Italy).

52 Ultrasound findings associated with pancreatic inflammation vary with the severity and chronicity of the
53 disease. Decreased echogenicity in AP reflects oedema, haemorrhage and necrosis, while the surrounding fat
54 is generally moderately hyperechoic. When significantly enlarged, the right lobe of the pancreas may move
55 from its normal position, dorsal or dorsomedial to the duodenum, to lie dorsolaterally. The stomach or
56 duodenum may become distended with fluid, showing wall thickening and lack of peristalsis, because of

57 functional ileus. Changes in the pancreas may be accompanied by localised or generalised accumulation of
58 peritoneal effusion. Severe pancreatitis can also result in generalised peritoneal effusion. The pancreatic duct
59 may be dilated and become as wide as the pancreatic-duodenal vein.⁹

60 Dogs were included in the study if data for the following 12 parameters were available: respiratory rate,
61 rectal temperature, WBC, Hct, total serum proteins, albumin, creatinine, cholesterol, total and ionic calcium,
62 sodium and potassium (Table 1). Complete blood count (Procyte DX, Idexx Laboratories), serum biochemis-
63 try profile (Liasys, Assel srl, Guidonia-Montecelio, Rome, Italy) and electrolytes (Stat Profile pHox Series
64 Analyzers, Nova Bio- medical, MA, USA) were performed by automated clinical analysers.

65 The following were exclusions from the study: previous diagnosis of AP, chronic kidney disease, diabetes
66 mellitus, hypothyroidism, hypoadrenocorticism, hyperadrenocorticism or pancreatic neoplasia.

67 Dogs were divided in two groups: survivors and non-survivors. Non- survivors included dogs that had died
68 within 7 days of hospital admission. Clinical and clinicopathological data were compared between survivors
69 and non-survivors. Cut-off values for serum creatinine and sodium were taken from the highest values in the
70 survivor group. Table 2 shows the cut-off values of serum sodium < 139.0 mmol/L (139.0 mEq/L), and
71 serum creatinine > 212 µmol/L (2.4 mg/dL). Odds ratio (OR) was calculated using these cut-off values. Data
72 were analysed with the Mann- Whitney test using Statgraphics Plus 5.1 (Manugistic Inc., Rockville, MD,
73 USA). A value of $P < 0.05$ was considered significant and $P < 0.01$ as highly significant.

74

75 Results

76 The study included 48 dogs (20 males, (18 intact, 2 neutered), 28 females, (19 intact, 9 spayed)) of several
77 breeds. The mean age was 9.2 ± 3.8 years.

78 The most commonly involved breeds were mixed breeds (14 dogs), Dachshund (3), Beagle (3), Siberian
79 Husky (3), Yorkshire Terrier (3), Boxer (2), Labrador Retriever (2), German Shepherd (2), English Set- ter
80 (2) and 1 each of 14 other breeds.

81 At clinical examination 43/48 dogs (89.6%) showed depression, anorexia/dysorexia, weight loss, nausea or
82 vomiting and diarrhoea. In addition to clinical signs of AP, 3 patients (6.2%) had respiratory dis- tress, 1
83 patient had ascites (2%), 1 had jaundice and 1 had hypovolaemic shock.

84 Table 1 reports the reference range, mean value and standard deviation for the 12 clinical and laboratory
85 parameters. Of the 48 dogs, 17 (35.4%) died within the first 48 h. Serum creatinine and sodium levels were
86 statistically associated with outcome in these canine cases of AP: $P = 0.017$ and $P = 0.004$, respectively
87 (Table 1). The remaining parameters (respiratory rate, temperature, Hct, WBC, total protein, albumin,
88 cholesterol, total calcium, calcium and potassium) did not show a significant difference between the survivor
89 and non-survivor groups. The presence of a left shift in the neutrophil count was present in 13 dogs (27%),
90 but was not associated with the outcome. Azotemia (OR 12.5; CI 1.32– 118.48) and hyponatremia (OR 4.9;
91 CI 1.36–17.64) were associated with an increased risk of death.

92

93 **Discussion**

94 This study concurrently used clinical signs (anorexia, lethargy, abdominal pain, vomiting), ultrasound
95 findings and abnormal SNAP® cPLTM test results as inclusion criteria for canine AP, as reported in a recent
96 work.¹⁰

97 The SNAP® cPLTM test is considered to be the most sensitive and specific marker of AP in dogs.^{11,12} To
98 the best of our knowledge, only one research group has simultaneously used the SNAP® cPLTM test,
99 abdominal ultrasound and clinicopathological findings as inclusion criteria for AP.¹⁰

100 Others have shown that the SNAP® cPLTM agrees with the Spec cPL test: 96–100% in normal canine
101 serum samples with normal levels of canine pancreatic lipase (cPL) and 88–92% for samples with an
102 elevated cPL.¹³

103 In the study by Pápa et al., a diagnosis of AP was based on the simultaneous presence of clinical signs of AP,
104 increased activity of serum amylase or lipase, ultrasonographic and/or macroscopic appearance and
105 cytological or histological evidence of AP.² Serum amylase and lipase have been reported to have a low
106 sensitivity (50% and 71%, respectively¹¹) and low specificity (50% and 43%, respec- tively¹¹). However, in
107 2008, Steiner et al. showed no correlation between elevated levels of lipase or amylase and canine AP.¹⁴

108 Mansfield et al. proposed a clinical severity index for canine AP.⁸ The diagnosis of AP was made on the
109 basis of an abdominal ultra- sound or histological examination. Although abdominal ultrasound is reported to
110 have a moderate sensitivity (68%¹⁵), no clear data are available regarding specificity.

111 However, abdominal ultrasound alone, based on purely morphological criteria, cannot unequivocally
112 identify a mild or recent inflammatory condition in which anatomical changes have not yet occurred.^{1,9,16}
113 Although pancreatic biopsy and histopathological examination are the best options for a diagnosis of AP,
114 they still have a limited feasibility in clinical practice.^{1,14}

115 A recent study, performed in dogs with clinical signs of acute abdominal disease (≥ 2 of the following
116 clinical signs: acute (< 2 days) onset of abdominal pain, vomiting, abdominal distension or diarrhoea),
117 highlighted the sensitivity (82%) and specificity (59%) of the SNAP® cPLTM test.¹⁷ Therefore, a positive
118 SNAP® cPLTM test result may provide a ‘false positive’ diagnosis for AP in up to 40% of dogs presenting
119 with abdominal pain.¹⁷ The specificity of the SNAP® cPLTM test decreased to 45% in dogs with
120 hyperadrenocorticism, which showed abnormal results, without clinical signs suggestive of AP.¹⁸ The
121 inclusion criteria and the use of multiple diagnostic modalities may have increased the significance of the
122 results in the present study.

123 It would be useful to identify a wide range of prognostic factors, possibly including clinical signs and
124 laboratory parameters commonly altered during canine AP.^{1,16,19} In the present study, the choice of 12
125 variables was based on the physiopathological mechanisms that occur during canine AP: respiratory rate,
126 rectal temperature, WBC, total serum protein and serum albumin are influenced by the magnitude of the
127 inflammation; serum creatinine concentration is associated with various degrees of hydration and, possibly,
128 with prerenal azotaemia; lower total calcium and ionised calcium concentrations may occur in peripancreatic
129 fat saponification.²⁰

130 Cholesterol disorders may be a cause or a consequence of AP,²⁰ while sodium and potassium levels are
131 influenced by gastrointestinal loss, kidney injury and inflammation.^{21,22}

132 Dogs with chronic kidney disease, diabetes mellitus, hypothyroidism, hypoadrenocorticism or
133 hyperadrenocorticism and dogs with a final diagnosis of pancreatic neoplasia were excluded because all
134 these diseases could be associated with AP and with abnormal SNAP® cPLTM test results. They could also
135 influence the clinical signs, mortality rate and laboratory parameters considered in this study.

136 In the present study, alterations in serum creatinine and sodium concentrations were identified as
137 significant factors of poor outcome in dogs with pancreatitis. Hypothermia at the time of admission was not

138 associated with a negative outcome, which is not in agreement with a previous study.² The remaining
139 parameters (respiratory rate, temperature, Hct, WBC, total protein, albumin, cholesterol, total calcium,
140 calcium and potassium) did not correlate with a poor prognosis.

141 In our study, OR values of serum creatinine and sodium supported the positive association between
142 azotaemia and negative outcome or hyponatraemia and negative outcome (Table 2).

143 Azotaemia has been reported as a prognostic marker in canine AP. Mansfield et al. found that dogs with a
144 renal damage score of 2 (anuria or azotaemia > 1.5-fold increase in serum urea and creatinine concentrations)
145 had a higher mortality rate than dogs with a renal damage score of 0 or 1. However, as the renal damage
146 score was part of a multi-organ clinical severity index, azotaemia was not directly associated with
147 prognosis.⁸ In another study, azotaemia was present in 55% of dogs with AP, but was not considered to have
148 prognostic significance.² Indeed, in human medicine, acute kidney injury (AKI) is a common complication
149 of severe pancreatitis, which increases the risk of death.^{23–25} AKI can be the result of hypoxaemia,
150 oxidative stress, decrease in renal perfusion and hypovolaemia caused by AP.²⁵ The use of serum
151 (symmetric dimethylarginine)²⁶ and urinary markers²⁷ (i.e. albumin, γ -glutamyl transferase) of AKI would
152 have been helpful to identify patients with preclinical grades of AKI.

153 During AP, hyponatraemia can occur because of gastrointestinal loss, peritoneal effusion, kidney injury and
154 systemic inflammatory response syndrome.^{28,29}

155 In our study, 89.6% of dogs showed vomiting or diarrhoea, so gastrointestinal loss was the most probable
156 cause of the hyponatraemia. Gut barrier damage could have played a prognostic role in these dogs, caused by
157 possible bacterial translocation.³⁰

158 Study limitations

159 There were a number of limitations to our study, including a lack of histopathology. It would also have been
160 interesting to assess urinary output and natriuresis because serum sodium is influenced by renal excretion
161 and anuric/oliguric patients have a worse outcome.³¹ Although patients with endocrine disorders were
162 excluded from the study, it is not possible to affirm that the dogs that died early did not have preclinical
163 stages of endocrine disorders.

164 Finally, although all the dogs in the present study received similar medical management, the AP therapy
165 included analgesia with opioid drugs, fluid therapy, antiemetic drugs, such as maropitant, and antacids,
166 such as ranitidine or omeprazole. None received fresh frozen plasma infusion. We did not consider the
167 effects of different drugs and dosages on mortality.

168 The present study examined prognostic parameters in canine AP that can be easily assessed in veterinary
169 clinical practice. At the time of diagnosis, the assessment of serum sodium and serum creatinine
170 concentrations may be helpful in evaluating the risk of death.

171

172 References

173 1. Xenoulis PG. Diagnosis of pancreatitis in dogs and cats. *J Small Anim Pract* 2015;56:13–26.

174 2. Pápa K, Máthé A, Abonyi-Tóth Z et al. Occurrence, clinical features and outcome of canine pancreatitis
175 (80 cases). *Acta Vet Hung* 2011;59:37–52.

176 3. Mentula P, Kylänpää ML, Kemppainen E et al. Early prediction of organ failure by combined markers in
177 patients with acute pancreatitis. *Br J Surg* 2005;92:68–75.

178 4. Kaya E, Dervisoglu A, Polat C. Evaluation of diagnostic findings and scoring systems in outcome
179 prediction in acute pancreatitis. *World J Gastroenterol* 2007;13:3090–3094.

180 5. Mofleh AI I-A. Severe acute pancreatitis: pathogenetic aspects and prognostic factors. *World J*
181 *Gastroenterol* 2008;14:675–684.

182 6. González-Gasch A, de Casasola GG, Martín RB et al. A simple prognostic score for risk assessment in
183 patients with acute pancreatitis. *Eur J Intern Med* 2009;20:43–48.

184 7. Pavlidis TE, Pavlidis ET, Sakantamis AK. Advances in prognostic factors in acute pancreatitis: a mini-
185 review. *Hepatobiliary Pancreat Dis Int* 2010;9:482–486. 8. Mansfield CS, James FE, Robertson ID.

186 Development of a clinical severity index for dogs with acute pancreatitis. *J Am Vet Med Assoc*

187 2008;233:936–944. 9. Penninck D. Pancreas. In: Penninck D, d’Anjou MA, editors. *Atlas of small animal*
188 *ultrasonography*. 1st edn. Blackwell Publishing, Oxford, 2008:319–337.

189 10. Tvarijonaviciute A, García-Martínez JD, Caldin M et al. Serum paraoxonase 1 (PON1) activity in acute
190 pancreatitis of dogs. *J Small Anim Pract* 2015;56:67–71.

- 191 11. Trivedi S, Marks SL, Kass PH et al. Sensitivity and specificity of canine pancreas-specific lipase (cPL)
192 and other markers for pancreatitis in 70 dogs with and without histopathologic evidence of pancreatitis. *J Vet*
193 *Intern Med* 2011;25:1241–1257.
- 194 12. McCord K, Morley PS, Armstrong J et al. A multi-institutional study evaluat- ing the diagnostic utility of
195 the spec cPLTM and SNAP® cPLTM in clinical acute pancreatitis in 84 dogs. *J Vet Intern Med*
196 2012;26:888–896.
- 197 13. Beall MJ, Cahill R, Pigeon K et al. Performance validation and method com- parison of an in-clinic
198 enzyme-linked immunosorbent assay for the detection of canine pancreatic lipase. *J Vet Diagn Invest*
199 2011;23:115–119.
- 200 14. Steiner JM, Newman S, Xenoulis P et al. Sensitivity of serum markers for pancreatitis in dogs with
201 macroscopic evidence of pancreatitis. *Vet Ther* 2008;9:263–273.
- 202 15. Hess RS, Saunders HM, Van Winkle TJ et al. Clinical, clinicopathologic, radio- graphic, and
203 ultrasonographic abnormalities in dogs with fatal acute pancreati- tis: 70 cases (1986–1995). *J Am Vet Med*
204 *Assoc* 1998;213:665–670.
- 205 16. Watson PJ, Bunch SE. The exocrine pancreas. In: Nelson RW, Couto CG, editors. *Small animal internal*
206 *medicine*. Mosby Elsevier, St Louis, 2009:579–606.
- 207 17. Haworth MD, Hosgood G, Swindells KL et al. Diagnostic accuracy of the SNAP and Spec canine
208 pancreatic lipase tests for pancreatitis in dogs present- ing with clinical signs of acute abdominal disease. *J*
209 *Vet Emerg Crit Care* 2014;24:135–143.
- 210 18. Mawby DI, Whittemore JC, Fecteau KA. Canine pancreatic-specific lipase concentrations in clinically
211 healthy dogs and dogs with naturally occurring hyperadrenocorticism. *J Vet Intern Med* 2014;28:1244–1250.
- 212 19. Watson PJ. Laboratory evaluation of exocrine pancreatic disease. In: Villiers E, Blackwood L, editors.
213 *BSAVA manual of canine and feline clinical pathology*. 2nd edn. BSAVA Publications, Gloucester,
214 2005:226–240.
- 215 20. Kamierczak SC. Biochemical indicators of acute pancreatitis. In: Lott JA, edi- tor. *Clinical pathology of*
216 *pancreatic disorders*. 1st edn. Humana Press, Totowa, 1997:75–124.
- 217 21. Mansfield C. Pathophysiology of acute pancreatitis: potential application from experimental models and
218 human medicine to dogs. *J Vet Intern Med* 2012;26:875–887.

219 22. Mansfield C. Acute pancreatitis in dogs: advances in understanding, diag- nostics, and treatment. *Top*
220 *Companion Anim Med* 2012;27:123–132.

221 23. Kes P, Vucicević Z, Ratković-Gusić I et al. Acute renal failure complicating severe acute pancreatitis.
222 *Renal Fail* 1996;18:621–628.

223 24. Halonen KI, Leppaniemi AK, Puolakkainen PA et al. Severe acute pancreati- tis: prognostic factors in
224 270 consecutive patients. *Pancreas* 2000;21:266–271. 25. Petejova N, Martinek A. Acute kidney injury
225 following acute pancreatitis: a review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*
226 2013;157:105–113.

227 26. Nabity MB, Lees GE, Boggess M, et al. Symmetric dimethylarginine assay validation, stability, and
228 evaluation as a marker for early detection of chronic kidney disease in dogs. *J Vet Intern Med*
229 2015;29:1036–1044.

230 27. De Loor J, Daminet S, Smets P et al. Urinary biomarkers for acute kidney injury in dogs. *J Vet Intern*
231 *Med* 2013;27:998–1010.

232 28. DiBartola SP. Disorders of sodium and water: hyponatremia and hyponatre- mia. In: *Fluid, electrolyte,*
233 *and acid-base disorders in small animal practice*. 4th edn. Saunders Elsevier, St Louis, 2012;45–79.

234 29. Kilpatrick S, Dreistadt M, Frowde P et al. Presence of systemic inflammatory response syndrome
235 predicts a poor clinical outcome in dogs with a primary hepatitis. *PLoS One* 2016;11:e0146560.

236 30. Qin HL, Su ZD, Gao Q et al. Early intrajejunal nutrition: bacterial transloca- tion and gut barrier function
237 of severe acute pancreatitis in dogs. *Hepatobiliary Pancreat Dis Int* 2002; 1:150–154.

238 31. Brown N, Segev G, Francey T et al. Glomerular filtration rate, urine produc- tion, and fractional
239 clearance of electrolytes in acute kidney injury in dogs and their association with survival. *J Vet Intern Med*
240 2015;29:28–34.

241